Skip to content

Formoterol MDI Phase 2 Dose Finding Study - Investigation on Adult Patients with Bronchial Asthma -

Formoterol MDI Phase 2 Dose Finding Study - Investigation on Adult Patients with Bronchial Asthma -

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220645
Enrollment
Unknown
Registered
2009-02-03
Start date
2009-02-03
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult patients with bronchial asthma

Interventions

investigational material(s) Generic name etc : KRP-108(FORMTEROL) INN of investigational material : Therapeutic category code : 225 Bronchodilators Dosage and Administration for Investigational mater

Sponsors

Kyorin Pharmaceutical Co.,LTD
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Adult patients with bronchial asthma who will meet all of the following criteria are to be enrolled in this study. -Age: 16 years or more (at obtaining informed consent) -Inpatient or outpatient: Not considered -Disease severity: Mild to moderate -Reversibility: Patients who present with the reversible air flow limitation etc.

Exclusion criteria

Exclusion criteria: The patients are not to be eligible for the study when they will fall into any of the following criteria. -Patients with complication or medical history of heart failure, myocardial infarction, angina, and the other heart disease. -Patients with complication of tuberculous disease, and respiratory infection, or medical history within one month before the run-in period -Patients with complication of irreversible pulmonary disease including COPD, and pulmonary fibrosis etc.

Design outcomes

Primary

MeasureTime frame
FEV 1.0 value

Secondary

MeasureTime frame
Pulmonary function test values, PEF value,asthma symptom score, etc.

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026